^
    Back
    Association details:
    Biomarker:Chr del(17p)
    Cancer:Small Lymphocytic Lymphoma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    CLL/SLL with del(17p)/TP53 mutation: Relapsed/refractory therapy...Preferred regimens…Venetoclax
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Chronic Lymphocytic Leukemia)
    New
    Excerpt:
    Venclyxto monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor.